On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev™. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 22 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 15 Number […]
On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]
On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 9 Number […]
Akebia Therapeutics, Inc. (AKBA) announced positive top-line results on May 5 for the first of its two Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of Akebia’s drug vadadustat. The drug treats anemia due to chronic kidney disease in adult patients on kidney dialysis. The studies indicate that the treatment […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: March Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 77% Avg Increase – Next open to 5-day Peak 5% Other stats: Number of signals over $10/share 6 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: February Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 85% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 7 Number […]
On February 26, InflaRx, N.V. (IFRX) announced positive initial data from the first 5 patients enrolled in its Phase IIa open label clinical trial for IFX-1. Two out of the five patients achieved complete remission of Pyoderma Gangraenosum (PG), a rare and debilitating autoinflammatory skin disease. Although the exact prevalence of PG is unknown, current […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 18 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 11 Number […]
Simply register below to get sample signals as they come out!
